The incidence of MM shows an increasing trend year by year ( 1 , 3 ), and currently ranks the second among hematological malignancies, second only to non-Hodgkin’s lymphoma ( 4 ).
← all excerpts
Network pharmacology- and molecular docking-based investigation of the therapeutic potential and mechanism of daucosterol against multiple myeloma.
1
—
—